DRUG INDUCED MITOCHONDRIAL TOXICITY: MECHANISTIC DIVERSITY AND DELETERIOUS CONSEQUENCES FOR THE LIVER

Pharma courses

Pharma Admission

pharma courses

pharma admission



{ DOWNLOAD AS PDF }

About Authors:
Keyur S. Patel*, Mital Mehta
Department of Pharmacology,
Anand Pharmacy College, Anand.
Gujarat, India.
keyurpatel200189@gmail.com

Abstract
Drug-induced liver injury (DILI) has become a leading cause of severe liver disease and withdrawal of an approved drug from the market. DILI accounts for acute liver failure, liver transplantation or death in the United States today. A recent retrospective study indicates that the risk of DILI is enhanced when the administered daily dosage is higher than 50 mg or when the drug undergoes significant liver metabolism. Hence airs a major clinical and regulatory challenge.
This review Sum up Direct mitochondrial impairment and Specific drug induced mitochondrial dysfunction, current mechanistic concepts of DILI in a 2-step model that limits its principle mechanisms to this main ways of initial injury. Umpteen Studies that evaluate the risk of hepatotoxicity from Statins in Hyperlipidemic Patients.  In this article, It will review the pathogenesis of drug induced mitochondrial liver toxicity and deleterious consequences of Atorvastatin.

REFERENCE ID: PHARMATUTOR-ART-2095

PharmaTutor (ISSN: 2347 - 7881)

Volume 2, Issue 1

Received On: 28/012/2014; Accepted On: 04/01/2014; Published On: 15/01/2014

How to cite this article: KS Patel, M Mehta, Drug Induced Mitochondrial Toxicity: Mechanistic Diversity and Deleterious Consequences for the liver, PharmaTutor, 2014, 2(1), 33-39

Introduction
More than 1000 drugs have been implicated in causing liver injury and it is the most common reason for a drug to be withdrawn from the market. Drug induced liver injury is responsible for 5% of all hospital admissions and 50% of all acute liver failures.1The mechanisms of DILI are not always known, but when they are investigated mitochondrial dysfunction is often present. Importantly, drug-induced mitochondrial dysfunction can be due to the drug itself and/or to reactive metabolites generated through cytochrome P450-mediated metabolism. These mitochondrial disturbances can have a variety of deleterious consequences, such as oxidative stress, energy shortage, accumulation of triglycerides (steatosis), and cell death.2

Mitochondrial structure and functions
Mitochondrial membrane permeabilization and cell death:
Mitochondria are organelles with two membranes surrounding a space (matrix) containing various enzymes and the mitochondrial genome (mtDNA). The inner membrane, which also harbours many enzymes, behaves as a barrier that is poorly permeable to various molecules3. Thus, this membrane contains transporters allowing the entry of endogenous compounds (ADP, fatty acids, glutathione, pyruvic acid) and possibly xenobiotics as well. In some pathophysiological circumstances, the mitochondrial membranes can lose their structural and functional integrity, in particular after the opening of the mitochondrial permeability transition pores (MPTP)4. These pores involve at least 4 candidate proteins, namely the peripheral benzodiazepine receptor (PBR), the voltage-dependent anion channel (VDAC), the adenine nucleotide translocase (ANT), and cyclophilin D4. The later protein (a modulator of the pore rather than a MPTP component per se11) is able to bind the immunosuppressive drug cyclosporine A that therefore reduces the opening probability of the MPTP. In contrast, several drugs and toxic compounds, but also high levels of some endogenous derivatives (e.g. calcium, fatty acids, and bile salts) can induce MPTP opening. As the latter event strongly alters mitochondrial function and structure, it can endanger cell life. However, the exact pathway whereby the cell will die (namely apoptosis or necrosis) depends on the number of mitochondria harboring opened MPTP5-7. If numerous mitochondria present opened MPTP, ATP stores will slump rapidly and necrosis will occur through a sudden rise in intracellular calcium levels because ATP is mandatory for the activity of the plasma membrane calcium ATPase (PMCA), an enzyme responsible for calcium extrusion out of the cell. In contrast, if MPTP opening takes place only in some mitochondria, ATP levels will be maintained thanks to undamaged organelles. However, the rare mitochondria involved in MPTP opening will swell allowing the release of different pro-apoptotic proteins including the apoptosis inducing factor (AIF), several caspases, and cytochrome c8. This key protein of the respiratory chain, when released in the cytoplasm, can bind to the Apaf-1 protein and ATP thus initiating the apoptotic pathway through the activation of caspases 9 and 3. Consequently, MPTP opening in a few mitochondria can also have deleterious consequences.

Several important points must be discussed regarding mitochondrial membrane permeabilization. Firstly, MPTP opening initially permeabilizes the mitochondrial inner membrane without alteration of the outer membrane. However, MPTP opening causes an equilibration of solutes with molecular masses up to 1500 Da and the massive entry of water into the matrix, which causes unfolding of the inner membrane and mitochondrial swelling. The latter event thus induces outer membrane rupture and the release of several mitochondrial proteins located in the intermembrane space (e.g. cytochrome c and AIF), which trigger apoptotis4, 8, 9. Secondly, mitochondrial membrane permeabilization can induce the release of cytochrome c and other cytotoxic proteins without any rupture of the mitochondrial outer membrane8, 10.This scenario requires the formation of pores within this membrane thanks to the association of two proapoptotic proteins belonging to the Bcl-2 family, namely Bak (already located in the outer membrane) and Bax (which is recruited from the cytosol)4, 8. Importantly, mitochondrial outer membrane permeabilization through the formation of Bax/ Bak pores is not sensitive to cyclosporine-A11, 12. Thus, whatever the mechanism involved in membrane permeabilization, this event can strongly alter mitochondrial function and structure, and thus lead to cell death. Finally, it is noteworthy that the MPTP structure seems to be different from one tissue to another. This may explain why some organs could be more or less vulnerable to certain permeability transition inducers13, 14.

Mitochondrial production of reactive oxygen species
A major feature of the mitochondria is the production of reactive oxygen species (ROS) through the activity of the mitochondrial respiratory chain (MRC)15, 16. Indeed, a small fraction of electrons entering the MRC can prematurely escape from complexes I and III and directly react with oxygen to generate the superoxide anion radical. This radical is then dismutated by the mitochondrial manganese superoxide dismutase (MnSOD) into hydrogen peroxide (H2O2), which is detoxified into water by the mitochondrial glutathione peroxidise (GPx) that uses reduced glutathione (GSH) as a cofactor. Hence, in the normal (non-diseased) state, most of the ROS generated by the MRC are detoxified by the mitochondrial antioxidant defences. The remaining (i.e. non-detoxified) ROS diffuse out of mitochondria and serve as second messengers to trigger cellular processes such as mitogenesis15. However, this detoxification process can be overwhelmed in different pathophysiological circumstances. This occurs in particular in case of GSH depletion within liver mitochondria, which reduces greatly their capability to detoxify H2O2 since they do not have catalase17. Depletion of mitochondrial GSH below a critical threshold thus favours H2O2 accumulation by impairing its detoxification. This in turn triggers mitochondrial dysfunction, MPTP opening, activation of c-Jun-N-terminal kinase (JNK), and cell death18, 19. Chronic ethanol intoxication, fasting, and malnutrition are diseased states favouring GSH depletion, in particular within mitochondria. Mitochondrial anti-oxidant enzymes can also be overwhelmed when MRC is chronically impaired. Indeed, a partial block in the flow of electrons greatly increases the probability of monoelectronic reduction of oxygen and superoxide anion production within the complexes I and III 20, 21. High steady state levels of ROS then damage OXPHOS proteins, cardiolipin, and mtDNA22-24. This oxidative damage aggravates mitochondrial dysfunction to further augment electron leakage and ROS formation, thus leading to a vicious circle25.

Drug-induced mitochondrial dysfunction and liver injury
Drug-induced adverse events and mitochondrial toxicity
The view that drugs could disturb mitochondrial function emerged several decades ago when clinical studies reported in some medicated individuals the occurrence of symptoms usually observed in patients presenting a mitochondrial disease of genetic origin or a Reye’s syndrome (whose physiopathology involves severe mitochondrial dysfunction)26. Likewise, myopathy, lactic acidosis, and hepatic steatosis have been reported in the late 80’s and early 90’s in patients treated with the antiretroviral nucleoside reverse transcriptase inhibitors (NRTIs) zidovudine (AZT), zalcitabine (ddC), didanosine (ddI) and stavudine (d4T)26-29. Since then, the list of drugs inducing adverse events due to mitochondrial dysfunction has not ceased to grow year after year. Regarding drug-induced liver diseases, different mechanisms of mitochondrial dysfunction have been described thus far, including membrane permeabilization, OXPHOS impairment, FAO inhibition, and mtDNA depletion5, 6, 26. Importantly, DILI due to mitochondrial toxicity has led to the interruption of clinical trials, or drug withdrawal after marketing, in particular when the benefit/risk ratio was deemed to be too low for the patient’s healthiness. Moreover, some marketed drugs have received Black Box warnings from drug agencies due to mitochondrial dysfunction and related hepatotoxicity5, 30.

Drug-induced MPTP opening
MPTP opening is one mechanism whereby drugs can induce cytolytic hepatitis5, 11, 31-35. Among these drugs, disulfiram can also induce mitochondrial membrane permeabilization through a MPTP-independent mechanism11. The precise mechanisms whereby drugs can induce MPTP opening are not known although recent investigations suggest at least three hypotheses, which are not mutually exclusive. Firstly, drugs can interact with some MPTP components 34. Secondly, drug-induced oxidative stress can favor the oxidation of regulatory thiol groups located within some MPTP components11, 36-40. Thirdly, drugs such as APAP and cisplatin could cause mitochondrial permeability transition through activation of JNK or other endogenous MPTP inducers19, 38, 41, 42.

NOW YOU CAN ALSO PUBLISH YOUR ARTICLE ONLINE.

SUBMIT YOUR ARTICLE/PROJECT AT articles@pharmatutor.org

Subscribe to Pharmatutor Alerts by Email

FIND OUT MORE ARTICLES AT OUR DATABASE


 

Pages

FIND MORE ARTICLES